Literature DB >> 16987243

Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin generates the AT100 epitope.

Hirotaka Yoshida1, Michel Goedert.   

Abstract

Microtubule-associated protein tau in a hyperphosphorylated state is the major component of the filamentous lesions that define a number of neurodegenerative diseases, including Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, argyrophilic grain disease and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Previous work has established that the phosphorylation-dependent anti-tau antibody AT100 is a specific marker for filamentous tau in adult human brain. Here we have identified protein kinases that generate the AT100 epitope in vitro and have used them, in conjunction with site-directed mutagenesis of tau, to map the epitope. We show that the sequential phosphorylation of recombinant tau by cAMP-dependent protein kinase (PKA) and the stress-activated protein kinases SAPK4/p38delta or JNK2 generated the AT100 epitope and that this required phosphorylation of T212, S214 and T217. Tau protein from newborn, but not adult, mouse brain was weakly labelled by AT100. Phosphorylation by PKA and SAPK4/p38delta abolished the ability of tau to promote microtubule assembly, but failed to influence significantly the heparin-induced assembly of tau into filaments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987243     DOI: 10.1111/j.1471-4159.2006.04052.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  35 in total

1.  Pseudophosphorylation of tau protein directly modulates its aggregation kinetics.

Authors:  Edward Chang; Sohee Kim; Kelsey N Schafer; Jeff Kuret
Journal:  Biochim Biophys Acta       Date:  2010-10-23

2.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

3.  HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.

Authors:  Julia Elisa Sepulveda-Diaz; Seyedeh Maryam Alavi Naini; Minh Bao Huynh; Mohand Ouidir Ouidja; Constantin Yanicostas; Sandrine Chantepie; Joao Villares; Foudil Lamari; Estelle Jospin; Toin H van Kuppevelt; Ayikoe Guy Mensah-Nyagan; Rita Raisman-Vozari; Nadia Soussi-Yanicostas; Dulce Papy-Garcia
Journal:  Brain       Date:  2015-04-04       Impact factor: 13.501

4.  The earliest tau dysfunction in Alzheimer's disease? Tau phosphorylated at s422 as a toxic seed.

Authors:  Kellen Voss; John Koren; Chad A Dickey
Journal:  Am J Pathol       Date:  2011-09-28       Impact factor: 4.307

5.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

6.  Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.

Authors:  Patrice Delobel; Isabelle Lavenir; Graham Fraser; Esther Ingram; Max Holzer; Bernardino Ghetti; Maria Grazia Spillantini; R Anthony Crowther; Michel Goedert
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

7.  Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Authors:  Michelle L Steinhilb; Dora Dias-Santagata; Tudor A Fulga; Daniel L Felch; Mel B Feany
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

8.  Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer's disease.

Authors:  Mirta Borin; Claudia Saraceno; Marcella Catania; Erika Lorenzetto; Valeria Pontelli; Anna Paterlini; Silvia Fostinelli; Anna Avesani; Giuseppe Di Fede; Gianluigi Zanusso; Luisa Benussi; Giuliano Binetti; Simone Zorzan; Roberta Ghidoni; Mario Buffelli; Silvia Bolognin
Journal:  Acta Neuropathol Commun       Date:  2018-07-13       Impact factor: 7.801

9.  Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene].

Authors:  Ana Velasco; Graham Fraser; Patrice Delobel; Bernardino Ghetti; Isabelle Lavenir; Michel Goedert
Journal:  FEBS Lett       Date:  2008-02-20       Impact factor: 4.124

10.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.